Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Metabolism
  4. Volume 25, Issue 7
  5. Article
Volume 25, Issue 7
  • ISSN: 1389-2002
  • E-ISSN: 1875-5453
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Objective

Various population pharmacokinetic (PPK) models have been established to help determine the appropriate dosage of docetaxel, however, no clear consensus on optimal dosing has been achieved. The purpose of this study is to perform an external evaluation of published models in order to test their predictive performance, and to find an appropriate PPK model for Chinese breast cancer patients.

Methods

A systematic literature search of docetaxel PPK models was performed using PubMed, Web of Science, China National Knowledge Infrastructure, and WanFang databases. The predictive performance of eleven identified models was evaluated using prediction-based and simulation-based diagnostics on an independent dataset (112 docetaxel concentrations from 56 breast cancer patients). The -2×log (likelihood) and Akaike information criterion were also calculated to evaluate model fit.

Results

The median prediction error of eight of the eleven models was less than 10%. The model fitting results showed that the three-compartment model of Bruno had the best prediction performance and that the three compartment model of Wang had the best simulation effect. Furthermore, although the covariates that significantly affect PK parameters were different between them, seven models demonstrated that docetaxel PK parameters were influenced by liver function.

Conclusions

Three compartment PPK models may be predictive of optimal docetaxel dosage for Chinese breast cancer patients. However, for patients with impaired liver function, the choice of which model to use to predict the blood concentration of docetaxel still requires great care.

© 2024 Bentham Science Publishers
© 2024 The Author(s). Published by Bentham Science Publisher. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cdm/10.2174/0113892002322494240816032948
2024-08-16
2025-01-10

  • From This Site

    /content/journals/cdm/10.2174/0113892002322494240816032948
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cdm/25/7/CDM-25-7-02.html?itemId=/content/journals/cdm/10.2174/0113892002322494240816032948&mimeType=html&fmt=ahah

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. VuongB. JacintoA.I. ChangS.B. KuehnerG.E. SavitzA.C. Contemporary review of the management and treatment of young breast cancer patients. Clin. Breast Cancer.2024S1526-82092400148410.1016/j.clbc.2024.06.001 38972829
     [Google Scholar]
  3. DingR. XiaoY. MoM. ZhengY. JiangY.Z. ShaoZ.M. Breast cancer screening and early diagnosis in Chinese women.Cancer Biol. Med.202219445046710.20892/j.issn.2095‑3941.2021.0676 35380032
     [Google Scholar]
  4. WeiJ. ZhangY. LiZ. LiX. ZhaoC. Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients.Ann. Transl. Med.2022101270510.21037/atm‑22‑2619 35845493
     [Google Scholar]
  5. ClarkeS.J. RivoryL.P. Clinical pharmacokinetics of docetaxel.Clin. Pharmacokinet.19993629911410.2165/00003088‑199936020‑00002 10092957
     [Google Scholar]
  6. ValeroV. Primary chemotherapy with docetaxel for the management of breast cancer.Oncology (Williston Park)2002166Suppl. 63543 12108896
     [Google Scholar]
  7. MeiT. AnX. ZhanJ. FengK. LiaoH. ZhaoC. LiS. Docetaxel exposure and hematological toxicity in Chinese patients with locally advanced/metastatic nasopharyngeal carcinoma.Int. J. Clin. Pharmacol. Ther.202159321622310.5414/CP203668 33191902
     [Google Scholar]
  8. KenmotsuH. TanigawaraY. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose.Cancer Sci.2015106549750410.1111/cas.12647 25728850
     [Google Scholar]
  9. NieuweboerA.J.M. de MorréeE.S. de GraanA.J.M. SparreboomA. de WitR. MathijssenR.H.J. Inter-patient variability in docetaxel pharmacokinetics: A review.Cancer Treat. Rev.201541760561310.1016/j.ctrv.2015.04.012 25980322
     [Google Scholar]
  10. SynN.L.X. WangL. WongA.L.A. SoeM.Y. ChuahB. ChanD. TanS.H. SooR.A. LeeS.C. GohB.C. YongW.P. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.Cancer Sci.2016107217318010.1111/cas.12856 26663719
     [Google Scholar]
  11. MaY. LinQ. YangY. LiangW. SalamoneS.J. LiY. LinY. ZhaoH. ZhaoY. FangW. HuangY. ZhangL. Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients.Ann. Transl. Med.20208523610.21037/atm.2020.01.76 32309383
     [Google Scholar]
  12. GuoJ. LinW. WengY. ChenY. ZengS. LinJ. ZhengX. LiX. LinM. YuX. ChenQ. Optimal exposure to docetaxel in adjuvant chemotherapy for early‐stage breast cancer.J. Clin. Pharm. Ther.202247122205221310.1111/jcpt.13793 36418195
     [Google Scholar]
  13. HeinemanT. BaumgartM. NanavatiC. GabrailN. Van WartS.A. MagerD.E. ManevalD.C. FathallahA.M. SekulovichR.E. Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer.Clin. Transl. Sci.20211451875188510.1111/cts.13041 33982408
     [Google Scholar]
  14. EngelsF.K. LoosW.J. van der BolJ.M. de BruijnP. MathijssenR.H.J. VerweijJ. MathotR.A.A. Therapeutic drug monitoring for the individualization of docetaxel dosing: A randomized pharmacokinetic study.Clin. Cancer Res.201117235336210.1158/1078‑0432.CCR‑10‑1636 21224369
     [Google Scholar]
  15. BakerS.D. VerweijJ. CusatisG.A. van SchaikR.H. MarshS. OrwickS.J. FrankeR.M. HuS. SchuetzE.G. LambaV. MessersmithW.A. WolffA.C. CarducciM.A. SparreboomA. Pharmacogenetic pathway analysis of docetaxel elimination.Clin. Pharmacol. Ther.200985215516310.1038/clpt.2008.95 18509327
     [Google Scholar]
  16. BrunoR. VivierN. VergniolJ.C. De PhillipsS.L. MontayG. SheinerL.B. A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation.J. Pharmacokinet. Biopharm.199624215317210.1007/BF02353487 8875345
     [Google Scholar]
  17. XieY. JinX. YanS. WuC. XiangB. WangH. LiangW. YangB. XiaoX. LiZ. PeiQ. ZuoX. PengY. Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients.Front. Pharmacol.20221396741210.3389/fphar.2022.967412 36105229
     [Google Scholar]
  18. ZangY.N. GuoW. DongF. LiA.N. de LeonJ. RuanC.J. Published population pharmacokinetic models of valproic acid in adult patients: A systematic review and external validation in a Chinese sample of inpatients with bipolar disorder.Expert Rev. Clin. Pharmacol.202215562163510.1080/17512433.2022.2075849 35536685
     [Google Scholar]
  19. ZhouY. LongE. ShiT. WangZ. ZhaoJ. LiuH. LinY. JiangM. LaoH. GeW. CuiY. External validation of vancomycin population pharmacokinetic models in ten cohorts of infected Chinese patients.J. Glob. Antimicrob. Resist.20223016317210.1016/j.jgar.2022.05.016 35640870
     [Google Scholar]
  20. Launay-IliadisM.C. BrunoR. CossonV. VergniolJ.C. Oulid-AissaD. MartyM. ClavelM. AaproM. Le BailN. IliadisA. Population pharmacokinetics of docetaxel during phase I studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation.Cancer Chemother. Pharmacol.1995371-2475410.1007/BF00685628 7497596
     [Google Scholar]
  21. SlavieroK.A. ClarkeS.J. McLachlanA.J. BlairE.Y.L. RivoryL.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.Br. J. Clin. Pharmacol.2004571445310.1046/j.1365‑2125.2003.01956.x 14678339
     [Google Scholar]
  22. MinamiH. KawadaK. SasakiY. TaharaM. IgarashiT. ItohK. FujiiH. SaekiT. OzawaK. SatoH. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.Cancer Sci.2009100114414910.1111/j.1349‑7006.2009.00992.x 19018756
     [Google Scholar]
  23. OnoueH. YanoI. TanakaA. ItoharaK. HanaiA. IshiguroH. MotohashiH. MasudaS. MatsubaraK. Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach.Eur. J. Clin. Pharmacol.201672670371010.1007/s00228‑016‑2031‑3 26905999
     [Google Scholar]
  24. CrombagM.R.B.S. DorloT.P.C. van der PanE. van StratenA. BergmanA.M. van ErpN.P. BeijnenJ.H. HuitemaA.D.R. Exposure to docetaxel in the elderly patient population: A population pharmacokinetic study.Pharm. Res.2019361218110.1007/s11095‑019‑2706‑4 31732882
     [Google Scholar]
  25. PatilA. ShriyanB. MehtaP. PatilM. GurjarM. NookalaM. PatilV. JoshiA. NoronhaV. PrabhashK. GotaV. ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients.Cancer Med.202110144948495610.1002/cam4.4026 34156160
     [Google Scholar]
  26. MoherD. ShamseerL. ClarkeM. GhersiD. LiberatiA. PetticrewM. ShekelleP. StewartL.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Syst. Rev.201541110.1186/2046‑4053‑4‑1 25554246
     [Google Scholar]
  27. WangG. ZhangY. WangX. SunQ. XunZ. YuanM. LiZ. Long-acting versus short-acting granulocyte colony-stimulating factors among cancer patients after chemotherapy in China.Medicine (Baltimore)202110051e2821810.1097/MD.0000000000028218 34941082
     [Google Scholar]
  28. WangG. LinZ. WangX. SunQ. XunZ. XingB. LiZ. The association between 5, 10 – methylenetetrahydrofolate reductase and the risk of unexplained recurrent pregnancy loss in China.Medicine (Baltimore)202110017e2548710.1097/MD.0000000000025487 33907097
     [Google Scholar]
  29. AldazA. SchaiquevichP. AramendíaJ.M. A pharmacometrics model to define docetaxel target in early breast cancer.Br. J. Clin. Pharmacol.202389272773610.1111/bcp.15526 36098504
     [Google Scholar]
  30. WangD. JacksonC. HungN. HungT. KwanR. ChanW.K. QinA. Hughes-MedlicottN.J. GlueP. DuffullS. Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel.J. Pharmacokinet. Pharmacodyn.202451433535210.1007/s10928‑024‑09913‑y 38504032
     [Google Scholar]
  31. YuH. JanssenJ.M. SawickiE. van HasseltJ.G.C. de WegerV.A. NuijenB. SchellensJ.H.M. BeijnenJ.H. HuitemaA.D.R. A population pharmacokinetic model of oral docetaxel coadministered with ritonavir to support early clinical development.J. Clin. Pharmacol.202060334035010.1002/jcph.1532 31595980
     [Google Scholar]
  32. KoolenS.L.W. OostendorpR.L. BeijnenJ.H. SchellensJ.H.M. HuitemaA.D.R. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co‐administration of ritonavir in patients with advanced cancer.Br. J. Clin. Pharmacol.201069546547410.1111/j.1365‑2125.2010.03621.x 20573082
     [Google Scholar]
  33. SahasrabudheS.A. BonateP.L. Pharmacokinetic comparability between two populations using nonlinear mixed effect models: A Monte Carlo study.J. Pharmacokinet. Pharmacodyn.202350318920110.1007/s10928‑023‑09842‑2 36708443
     [Google Scholar]
  34. RileyR.D. SnellK.I.E. ArcherL. EnsorJ. DebrayT.P.A. van CalsterB. van SmedenM. CollinsG.S. Evaluation of clinical prediction models (part 3): Calculating the sample size required for an external validation study.BMJ2024384e07482110.1136/bmj‑2023‑074821 38253388
     [Google Scholar]
  35. HanafinP.O. NationR.L. ScheetzM.H. ZavasckiA.P. SandriA.M. KwaA.L. CherngB.P.Z. KubinC.J. YinM.T. WangJ. LiJ. KayeK.S. RaoG.G. Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.CPT Pharmacometrics Syst. Pharmacol.202110121525153710.1002/psp4.12720 34811968
     [Google Scholar]
  36. CoronaG. EliaC. CasettaB. High-throughput plasma docetaxel quantification by liquid chromatography–tandem mass spectrometry.Clin. Chim. Acta20114123-435836410.1016/j.cca.2010.11.010
     [Google Scholar]
  37. DuP. LiN. WangH. YangS. SongY. HanX. ShiY. Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma.J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.201392610110710.1016/j.jchromb.2013.02.006 23567294
     [Google Scholar]
  38. ChoE.K. ParkJ.Y. LeeK.H. SongH.S. MinY.J. KimY.H. KangJ.H. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and taxotere injection, in patients with advanced solid cancer.Cancer Chemother. Pharmacol.201473191610.1007/s00280‑013‑2264‑0 24337589
     [Google Scholar]
  39. GaoS. ZhouJ. ZhangF. MiaoH. YunY. FengJ. TaoX. ChenW. Rapid and sensitive liquid chromatography coupled with electrospray ionization tandem mass spectrometry method for the analysis of paclitaxel, docetaxel, vinblastine, and vinorelbine in human plasma.Ther. Drug Monit.201436339440010.1097/FTD.0000000000000010 24365981
     [Google Scholar]
  40. FujitaK. YoshinoE. KawaraK. MaedaK. KusuharaH. SugiyamaY. YokoyamaT. KanetaT. IshidaH. SasakiY. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.Cancer Chemother. Pharmacol.201576479380110.1007/s00280‑015‑2844‑2 26297058
     [Google Scholar]
  41. GengC. LiP. ChenX. YuanG. GuoN. LiuH. ZhangR. GuoR. Comparison of the docetaxel concentration in human plasma measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and a nanoparticle immunoassay and clinical applications of that assay.Biosci. Trends201711220220810.5582/bst.2017.01029 28420860
     [Google Scholar]
  42. De CockR.F. PianaC. KrekelsE.H. The role of population PK-PD modelling in paediatric clinical research.Eur. J. Clin. Pharmacol.201167Suppl. 151610.1007/s00228‑009‑0782‑9
     [Google Scholar]
  43. WangJ. WuZ. LouZ. Establishment and validation of population pharmacokinetic model of docetaxel in malignant tumor patients.China Pharm2022331822612265
     [Google Scholar]
  44. ZhangG. PanQ. ZhuangQ. Population pharmacokinetics model of docetaxel by nonlinear mixed effect model.World Clin Drugs2012331222
     [Google Scholar]
  45. XiX. DongY. ZhaoC. Population pharmacokinetics of docetaxel in patients with solid tumors.J. Army Med. Univ.2022442234
     [Google Scholar]
  46. BellantiF. Della PasquaO. Modelling and simulation as research tools in paediatric drug development.European J. Clin. Pharmacol.201167Suppl. 1758610.1007/s00228‑010‑0974‑3
     [Google Scholar]
  47. WeiS. ChenJ. ZhaoZ. MeiS. External validation of population pharmacokinetic models of vancomycin in postoperative neurosurgical patients.Eur. J. Clin. Pharmacol.20237981031104210.1007/s00228‑023‑03511‑6 37261482
     [Google Scholar]
  48. ShenX. LiX. LuJ. ZhuJ. HeY. ZhangZ. ChenZ. ZhangJ. FanX. LiW. Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children.CPT Pharmacometrics Syst. Pharmacol.20241371201121310.1002/psp4.13151 38686551
     [Google Scholar]
  49. BrunoR. HilleD. RivaA. VivierN. ten Bokkel HuinninkW.W. van OosteromA.T. KayeS.B. VerweijJ. FossellaF.V. ValeroV. RigasJ.R. SeidmanA.D. ChevallierB. FumoleauP. BurrisH.A. RavdinP.M. SheinerL.B. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.J. Clin. Oncol.199816118719610.1200/JCO.1998.16.1.187 9440742
     [Google Scholar]
  50. HookerA.C. Ten TijeA.J. CarducciM.A. WeberJ. Garrett-MayerE. GelderblomH. McguireW.P. VerweijJ. KarlssonM.O. BakerS.D. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: Incorporating cytochrome P4503A activity measurements.Clin. Pharmacol. Ther.200884111111810.1038/sj.clpt.6100476 18183036
     [Google Scholar]
  51. FukaeM. ShiraishiY. HirotaT. SasakiY. YamahashiM. TakayamaK. NakanishiY. IeiriI. Population pharmacokinetic–Pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.Cancer Chemother. Pharmacol.20167851013102310.1007/s00280‑016‑3157‑9 27709284
     [Google Scholar]
  52. ChengJ. ShiQ. LiuZ. Validation of the population pharmacokinetic model of docetaxel in breast cancer patients.J. Bengbu Med. Coll.2020455638643
     [Google Scholar]
  53. YangJ. LiX. LiW. XiX. DuQ. PanF. LiuS. An improved LC–MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients.Biomed. Chromatogr.2020348e485710.1002/bmc.4857 32307730
     [Google Scholar]
  54. PuissetF. AlexandreJ. TreluyerJ-M. RaoulV. RochéH. GoldwasserF. ChatelutE. Clinical pharmacodynamic factors in docetaxel toxicity.Br. J. Cancer200797329029610.1038/sj.bjc.6603872 17595656
     [Google Scholar]
  55. WangF. ZhaoC. WenX. ZhengQ. LiL. Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer.Expert Rev. Clin. Pharmacol.202114101295130310.1080/17512433.2021.1976638 34488513
     [Google Scholar]
  56. HalabiS. DuttaS. TangenC.M. RosenthalM. PetrylakD.P. ThompsonI.M.Jr ChiK.N. AraujoJ.C. LogothetisC. QuinnD.I. FizaziK. MorrisM.J. EisenbergerM.A. GeorgeD.J. De BonoJ.S. HiganoC.S. TannockI.F. SmallE.J. KellyW.K. Overall survival of black and white men with metastatic castration-resistant prostate cancer treated with docetaxel.J. Clin. Oncol.201937540341010.1200/JCO.18.01279 30576268
     [Google Scholar]
  57. ChowL.W.C. BiganzoliL. LeoA.D. KuroiK. HanH.S. PatelJ. HuangC.S. LuY.S. ZhuL. ChowC.Y.C. LooW.T.Y. GlückS. ToiM. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients.Asia Pac. J. Clin. Oncol.201713637237810.1111/ajco.12682 28371190
     [Google Scholar]
  58. Mediavilla-VarelaM. PachecoF.J. AlmaguelF. PerezJ. SahakianE. DanielsT.R. LeohL.S. PadillaA. WallN.R. LillyM.B. De LeonM. CasianoC.A. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.Mol. Cancer2009816810.1186/1476‑4598‑8‑68 19715609
     [Google Scholar]
  59. HorS.Y. LeeS.C. WongC.I. LimY.W. LimR.C. WangL.Z. FanL. GuoJ.Y. LeeH.S. GohB.C. TanT. PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.Pharmacogenomics J.20088213914610.1038/sj.tpj.6500478 17876342
     [Google Scholar]
  60. GoeyA.K.L. MeijermanI. RosingH. MarchettiS. Mergui-RoelvinkM. KeessenM. BurgersJ.A. BeijnenJ.H. SchellensJ.H.M. The effect of St John’s wort on the pharmacokinetics of docetaxel.Clin. Pharmacokinet.201453110311010.1007/s40262‑013‑0102‑5 24068654
     [Google Scholar]
  61. GoeyA.K.L. MeijermanI. RosingH. BurgersJ.A. Mergui-RoelvinkM. KeessenM. MarchettiS. BeijnenJ.H. SchellensJ.H.M. The effect of E Chinacea purpurea on the pharmacokinetics of docetaxel.Br. J. Clin. Pharmacol.201376346747410.1111/bcp.12159 23701184
     [Google Scholar]
  62. LimY.W. GohB.C. WangL.Z. TanS.H. ChuahB.Y.S. LimS.E. IauP. BuhariS.A. ChanC.W. SukriN.B. CorderoM.T. SooR. LeeS.C. Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.Ann. Oncol.201021112175218210.1093/annonc/mdq230 20430905
     [Google Scholar]
/content/journals/cdm/10.2174/0113892002322494240816032948
Loading
A Cross-sectional Comparative Analysis of Eleven Population Pharmacokinetic Models for Docetaxel in Chinese Breast Cancer Patients
Current Drug Metabolism 25, 479 (2024); https://doi.org/10.2174/0113892002322494240816032948
/content/journals/cdm/10.2174/0113892002322494240816032948
/content/journals/cdm/10.2174/0113892002322494240816032948
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): breast cancer; docetaxel; External evaluation; hematological toxicity; population pharmacokinetics; predictive performance

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test